

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 1522-1001-1	SERIAL NO. 10/619545
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>			APPLICANT Lars OLSON et al.	
(37 CFR 1.98(b))			FILING DATE July 16, 2003	GROUP 1652

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
DR	AA	5,514,825	05/96	VULIGONDA et al.			
	AB						
	AC						

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
DR	AD	GB 2 292 522	02/96	United Kingdom			N/A

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

DR	AE	H. YOKOYAMA et al., <i>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</i> , Vol. 216, No. 1, 1995, "Upstream Structure of Human ADH7 Gene and the Organ Distribution of its Expression" page 216-222
	AF	M. ZGOMBYC-KNIGHT, <i>THE JOURNAL OF BIOLOGICAL CHEMISTRY</i> , Vol. 270, No. 9, March 1995, "Genomic Structure and expression of the ADH7 Gene Encoding Human Class IV alcohol Dehydrogenase, the Form Most Efficient for Retinol Metabolism in Vitro", pages 4305-4311
	AG	S. TA et al., <i>PROC. NATL. ACAD. SCI.</i> , Vol. 94, No. 26, December 1997, "Regulation of Dopaminergic Pathways by Retinoids: Activation of the D2 Receptor Promoter By Members of the Retinoic Acid receptor-Retinoid X Receptor Family", page 1439-14354
	AH	R.H. ZETTERSTROM et al., <i>MOLECULAR ENDOCRINOLOGY</i> , Vol. 10, No. 12, 1996, Retinoid X Receptor Heterodimerization and Developmental Expression Distinguish the Orphan Nuclear Receptors NGFI-B, Nurr1, and Nor1", page 1656-166
DR	AI	P. McCAFFERY et al., <i>PROC. NATL. ACAD. SCI.</i> , Vol. 91, August 1994, "High Levels of a Retinoic Acid-generating Dehydrogenase in the Meso-telencephalic Dopamine System", page 7772-7776

EXAMINER		DATE CONSIDERED	4/14/06
----------	---	-----------------	---------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT0-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1522-1001-1	SERIAL NO. <u>10/619545</u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Lars OLSON et al.	
37 CFR 1.98(b)		FILING DATE July 16, 2003	GROUP <u>1652</u>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

<u>DN</u>	AT	Buervenich et al., Mov. Disord 15:813-818, September, 2000
	AU	Tan et al., Neuroscience Letters 305:70-72, 2001
	AV	Zgombic-Knight et al., <del>J Biol. Chem.</del> 270:4305-4311, 1995, EMBL accession numbers U16286-U16293, 1995
	AX	Yokoyama et al., GenEMBL accession number L39009, March 7, 1996
<u>JR</u>	AY	Sage-Ono, GenEMBL accession number D85101, May 2, 1998

EXAMINER		DATE CONSIDERED	<u>4/14/06</u>
----------	---	-----------------	----------------

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1522-1001-1	SERIAL NO. 10/619545
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		APPLICANT Lars OLSON et al.	
37 CFR 1.98(b)		FILING DATE July 16, 2003	GROUP 1652

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

	DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
AI						
AJ						
AK						
AL						
AM						
AN						
AO						
AP						
AQ						

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

<i>DR</i>	AT	Glass et al., GenEMBL accession number U30500, September 1, 1995
	AU	Carson et al., GenEMBL AA080645, October 28, 1997
	AV	Mathews et al., GenEMBL accession number U17249, September 27, 1995
	AX	NCI-CGAP, GenEMBL accession number AA906249, May 19, 1998
<i>DR</i>	AY	King et al., GenEMBL accession number L41145, April 1, 1995

EXAMINER		DATE CONSIDERED
		4/14/06

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1522-1001-1	SERIAL NO. 10/619545
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>		APPLICANT Lars OLSON et al.	
37 CFR 1.98(b)		FILING DATE July 16, 2003	GROUP 1652

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

<i>JN</i>	AT	Bork, Genome Research, 10:348-400, 2000.
<i>JN</i>	AU	Broun et al., Science 282:1315-1317, 1998.
<i>JN</i>	AV	Van de Loo et al., Proc. Natl. Acad. Sci. 92:6743-6747, 1995
	AX	
	AY	

EXAMINER	<i>JN</i>	DATE CONSIDERED	4/14/06
----------	-----------	-----------------	---------

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.